Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Austin Strohbehn

Retina Specialist West Des Moines, IA Medical Doctor

NPI 1629482468 CMS profile 893371

6200 Westown Pkwy, West Des Moines, IA 50266

Open in the dashboard

General payments

$5,219

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$24,148 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Austin Strohbehn of West Des Moines, IA is reported in the CMS Open Payments database as having received $5,219 across 72 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $24,148 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 65th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,984 16
2024 General $994 28
2023 General $424 19
2022 General $382 8
2019 General $434 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Austin Strohbehn
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Austin Strohbehn were reported at $2,984. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Austin Strohbehn Retina Specialist median Middle half National median
2019 $434 $410 $157–$1,517 $163
2020 $0 $168 $65–$778 $114
2021 $0 $258 $101–$1,161 $132
2022 $382 $418 $162–$1,488 $149
2023 $424 $476 $178–$1,312 $160
2024 $994 $520 $188–$1,372 $164
2025 $2,984 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dutch Ophthalmic, USA $2,563 4 payments
  2. Regeneron Healthcare Solutions, Inc. $906 35 payments
  3. Alcon Vision LLC $584 2 payments
  4. Apellis Pharmaceuticals, Inc. $224 7 payments
  5. US Oncology Corporate, Inc. $222 1 payment
  6. Astellas Pharma US Inc $191 7 payments
  7. Bausch & Lomb Americas Inc. $171 8 payments
  8. AbbVie, Inc. $125 1 payment
  9. Genentech, Inc. $106 1 payment
  10. Harrow Eye, LLC $62 2 payments
  11. Other $66 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,969 71 payments
  2. Consulting Fee $2,250 1 payment
Products named General payments · program years 2019–2025
  1. EVA, combined machine $2,563 4 payments
  2. TISSUEBLUE $2,563 4 payments
  3. EYLEA $460 16 payments
  4. EYLEA HD $446 19 payments
  5. Syfovre $224 7 payments
  6. Izervay $173 6 payments
  7. NGENUITY $150 1 payment
  8. XIPERE $126 6 payments
  9. OZURDEX $125 1 payment
  10. VUITY $125 1 payment
  11. Other $341 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

671

Median for Ophthalmology: 891

Drug cost

$31,853

Median for Ophthalmology: $68,233

Branded share of claims

30%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 269 $14,268
Bromfenac Sodium Generic 19 $10,026
Moxifloxacin Moxifloxacin Hcl Brand 136 $3,216
Difluprednate Generic 11 $1,288
Dorzolamide Hcl Generic 51 $805
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 49 $681
Ketorolac Tromethamine Generic 17 $625
Brimonidine Tartrate Generic 42 $280
Latanoprost Generic 32 $249
Timolol Maleate Generic 29 $234

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$6,719,037

Of which drugs: $5,999,065

Medicare patients

1,388

Average age 79

Services billed

159,313

838 women, 550 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 33%
Chronic kidney disease 31%
Ischemic heart disease 28%
Depression 22%
Atrial fibrillation 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 410 142,020 $3,890,425
Injection, aflibercept, 1 mg J0178 Office 267 2,332 $1,507,639
Injection, ranibizumab, 0.1 mg J2778 Office 111 2,057 $251,087
Injection, aflibercept hd, 1 mg J0177 Office 31 720 $189,918
Injection, triamcinolone acetonide (xipere), 1 mg J3299 Office 11 768 $28,014

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $216
$216 — 720
Syfovre
  • Apellis Pharmaceuticals, Inc. $176
$176 — —
Izervay
  • Astellas Pharma US Inc $151
$151 — —
XIPERE
  • Bausch & Lomb Americas Inc. $45
$45 — 768
IHEEZO
  • Harrow Eye, LLC $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record